Skip to main content
. 2021 Jun 11;11(6):873. doi: 10.3390/biom11060873

Figure 4.

Figure 4

Chronic metformin treatment reduces blood glucose through interference of Foxo1-S273 phosphorylation. (A–C) Blood glucose in WT (A), FKO (B), and Foxo1S273A (C) mice chronically treated with 50 mg/kg body weight metformin after 16 h fasting, n = 5–7 mice/group. (D–F) Pyruvate tolerance test in WT (D), FKO (E), and Foxo1S273A (F) mice chronically treated with 50 mg/kg body weight metformin, n = 5–7 mice/group. (G–I) Glucose tolerance test in WT (G), FKO (H), and Foxo1S273A (I) mice chronically treated with 50 mg/kg body weight metformin, n = 5–7 mice/group. (J–L) Insulin tolerance test in WT (J), FKO (K), and Foxo1S273A (L) mice chronically treated with 50 mg/kg body weight metformin, n = 5–7 mice/group. All data are presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.